HHealthcare Read More Sirona Medical Raises $40M Series D as Platform Usage TriplesOctober 16, 2026 Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year.…
MMedication Read More New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one yearOctober 15, 2026 In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
MMedication Read More Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesSeptember 30, 2026 In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6…
HHealthcare Read More Oracle and Buck Institute for Research on Aging Advance Landmark Federal Aging Research InitiativeSeptember 23, 2026 Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a…
HHealthcare Read More Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02September 15, 2026 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02…
MMedication Read More Parker Waichman Applauds Health Canada and Australia for Strengthening NAION Safety Guidance for Certain GLP-1 MedicationsJuly 29, 2026 Canada now directs physicians to urgently evaluate sudden vision loss and discontinue Ozempic and Mounjaro if NAION is…
FFitness Read More Franchise Equity Partners Acquires Bravo Fit, Planet Fitness’ Australian FranchiseeJuly 21, 2026 Investment Advances Planet Fitness’ Commitment to Providing Accessible and Affordable Fitness Internationally and Targets Over 135 Planet Fitness…
HHealthcare Read More Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsJuly 18, 2026 AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
HHealthcare Read More Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, CanadaJuly 16, 2026 Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…
HHealthcare Read More Planet DDS and Truro Bring Predictive Intelligence to the Denticon Ecosystem: Transforming Patient-Facing Dental Operations for Capacity and Revenue OptimizationJuly 9, 2026 “I’m incredibly excited about our partnership with Truro AI because it solves a problem that has frustrated dental…
HHealth Read More Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 DiabetesJune 6, 2026 Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…
HHealth Read More Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE TrialJune 6, 2026 New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…